References

• Elmosalamy, A., Tarikogullari, I., Patarroyo-Rodriguez, L., Wilson, G., Vande Voort, J. L., Kung, S., Frye, M. A., & Singh, B. (2025). Intravenous ketamine versus esketamine for depression: A systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 15, 20451253251394127. https://doi.org/10.1177/20451253251394127
• Seshadri, A., Prokop, L. J., & Singh, B. (2024). Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: A systematic review and meta-analysis. Journal of Affective Disorders, 356, 379–384. https://doi.org/10.1016/j.jad.2024.03.137
• Singh, B., Kung, S., Pazdernik, V., Schak, K. M., Geske, J., Schulte, P. J., Frye, M. A., & Vande Voort, J. L. (2023). Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: An observational study. The Journal of Clinical Psychiatry, 84(2), Article 22M14548. https://doi.org/10.4088/JCP.22M14548